Novartis Ag (NVS) Total Current Liabilities (2009 - 2026)

Novartis Ag has reported Total Current Liabilities for 18 years, with the latest figure at $31.7 billion in Q2 2026.

• Quarterly Total Current Liabilities changed 0.11% year-over-year to $31.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $31.7 billion (changed 0.11% YoY) and the FY2025 annual result came in at $27.3 billion, down 4.93% from the prior year.
• Total Current Liabilities climbed to $31.7 billion in Q2 2026 per NVS's latest filing, from $27.3 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.9 billion in Q2 2023 and troughed at $26.4 billion in Q4 2023.
• A 5-year average of $29.1 billion and a median of $28.7 billion in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities increased 15.42% in 2023, then fell 13.47% in 2024.
• Over 5 years, Total Current Liabilities stood at $28.7 billion in 2022, then declined by 7.91% to $26.4 billion in 2023, then increased by 8.72% to $28.7 billion in 2024, then retreated by 4.93% to $27.3 billion in 2025, then increased by 16.39% to $31.7 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $31.7 billion, $27.3 billion, and $31.7 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.